16.12 0.00 (0.00%)
After hours: 4:41PM EDT
|Bid||15.96 x 1300|
|Ask||16.15 x 4000|
|Day's Range||16.08 - 16.43|
|52 Week Range||5.27 - 17.46|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.07|
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding ENDP is favorable, with net inflows of $20.59 billion.
The Zacks Analyst Blog Highlights: Ingersoll-Rand, Endo International, Glanbia and Smurfit Kappa Group
Francis Chou, a well-regarded Canadian value investor, the founder of Chou Associates Management, and Morningstar Fund Manager of the Decade in 2004, was once just an ordinary immigrant in Canada with $200 in his pocket. Even though he is Chinese, he was born and raised in India, and came to Canada looking for a job. For […]
Ireland's growth in the past few years not only shows its resilience to the economic downturn in the EU but also makes it one of the most business-friendly destinations of the region.
The biotech sector has seen some year-to-date strength, as reflected by the nearly 11-percent advance in the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ). The upward momentum became more pronounced ...
Endo expects to announce late-stage clinical trials results for its experimental cellulite treatment in the fourth quarter.
Endo (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jim Cramer zooms through his take on fans' favorite stocks in a special edition of the lightning round.
Endo International Plc is seeking to resolve all lawsuits over its Opana painkiller in a deal that would cap its legal exposure and pull it out of talks with other drugmakers and distributors seeking an industrywide settlement of opioid litigation, according to three people familiar with the talks. No numbers have yet been proposed in the talks between lawyers for Endo and attorneys for states, cities and counties, but there have been discussions about changing the way the company markets drugs, according to people who asked not to be named because the negotiations are private. With the U.S. facing an opioid overdose epidemic, Dublin-based Endo is trying to resolve more than 1,000 suits filed against it by state attorneys general and private lawyers representing cities and counties by the end of the year, the people said.
DUBLIN , Sept. 6, 2018 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that members of management will participate in a fireside chat at the Morgan Stanley 16 th Annual Global Healthcare ...
Biogen (BIIB) enrolls first patient in a phase III study evaluating BIIB093 for prevention and treatment of severe cerebral edema in large hemispheric infarction.
Endo (ENDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Esperion Therapeutics' (ESPR) combination regimen of bempedoic acid and Merck's Zetia achieves significant reduction in bad cholesterol in a phase III study.
Ionis Pharmaceuticals (IONS) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
The action was the first time the regulator has moved to exclude any substance from a list of ingredients that may be used to produce in bulk compounded medications that do not need to go through the agency's safety approval process. The other two substances are bumetanide and nicardipine hydrochloride, which the regulator said are also ingredients of one or more FDA-approved drug products.
The U.S. Food and Drug Administration on Monday proposed excluding three substances from a list of ingredients that could be used to manufacture compounded medications in bulk for use by hospitals and doctors' offices. The action was the first time the regulator has moved to exclude any substance from a list of ingredients that may be used to produce in bulk compounded medications that do not need to go through the agency's safety approval process. Shares of Endo jumped 5 percent.
Jazz Pharmaceuticals' (JAZZ) Vyxeos receives marketing approval from the European Commission for treating acute myeloid leukemia.
Zacks.com highlights: Medifast, Endo International, HCA Healthcare, Five9 and FTI Consulting